Fascin-1 is a novel biomarker of aggressiveness in some carcinomas

29Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Tremendous progress has been made in recent years towards the understanding, prevention and management of malignant disease, yet cancer remains a leading cause of global mortality and morbidity. Current approaches towards combating this disease include prevention, early detection and various treatment modalities. However, even with implementation of novel therapeutic options and preventative measures, most cancers are currently diagnosed at late stages, when treatment therapies are least effective. In a recent study published in BMC Medicine, Tan et al. performed a systematic review and meta-analysis to show that fascin-1, an actin-bundling protein, is associated with increased risk of mortality and metastasis in various cancer types. Although the study examined the association of fascin-1 with mortality, time-to-disease progression, lymph node metastasis and distant metastasis in five major cancer types, the clinical implications of these findings are still unclear and many unanswered questions remain.Please see related research article here http://www.biomedcentral.com/1741-7015/11/52. © 2013 Kulasingam and Diamandis; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Kulasingam, V., & Diamandis, E. P. (2013, February 26). Fascin-1 is a novel biomarker of aggressiveness in some carcinomas. BMC Medicine. https://doi.org/10.1186/1741-7015-11-53

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free